Business Update

Healthcare advisory firm says metabolic syndrome drug market offers opportunity

Published in Obesity and Diabetes Week, February 7th, 2005

Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that, as more drugs are developed to treat multiple conditions and risk factors, pharmaceutical companies need to achieve a better understanding of overlapping and co-morbid patient populations.

Totaling more than $30 billion, the metabolic syndrome drug market, which includes type 2 diabetes, obesity, dyslipidemia, and hypertension, is an example of such a co-morbid patient population that offers huge commercial opportunity.

To assist organizations in identifying the prevalent population of metabolic syndrome sufferers in the United States,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-02-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry